PharmaEssentia will present six studies examining treatment gaps and real-world BESREMi use in essential thrombocythemia and polycythemia vera. The findings include 55% two-year treatment persistence in first-line PV users and new molecular response data from Asian patient populations.
PharmaEssentia has secured FDA approval for BESREMi in adults with essential thrombocythemia after the Phase 3 SURPASS ET trial showed a 37.4% durable response rate versus 3.6% with anagrelide.
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.